Cargando…

The need to manage the risk of thromboembolism in COVID-19 patients

COVID-19 first appeared in Wuhan, Hubei Province, China, in December 2019. Thought to be of zoonotic origin, it has been named SARS-CoV-2 (COVID-19) and has spread rapidly. As of April 20, 2020, there have been >2.4 million cases recorded worldwide. The inflammatory process, cytokine storm, and l...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Inayat Hussain, Savarimuthu, Sugeevan, Leung, Marco Shiu Tsun, Harky, Amer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: by the Society for Vascular Surgery. Published by Elsevier Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7224653/
https://www.ncbi.nlm.nih.gov/pubmed/32417304
http://dx.doi.org/10.1016/j.jvs.2020.05.015
_version_ 1783533943662837760
author Khan, Inayat Hussain
Savarimuthu, Sugeevan
Leung, Marco Shiu Tsun
Harky, Amer
author_facet Khan, Inayat Hussain
Savarimuthu, Sugeevan
Leung, Marco Shiu Tsun
Harky, Amer
author_sort Khan, Inayat Hussain
collection PubMed
description COVID-19 first appeared in Wuhan, Hubei Province, China, in December 2019. Thought to be of zoonotic origin, it has been named SARS-CoV-2 (COVID-19) and has spread rapidly. As of April 20, 2020, there have been >2.4 million cases recorded worldwide. The inflammatory process, cytokine storm, and lung injury that are associated with COVID-19 can put patients at an increased risk of thrombosis. The total incidence of thrombotic events in COVID-19 patients is currently uncertain. Those with more severe disease and with other risk factors, including increasing age, male sex, obesity, cancer, comorbidities, and intensive care unit admission, are at higher risk of these events. However, there is little international guidance on managing these risks in COVID-19 patients. In this paper, we explore the current evidence and theories surrounding thrombosis in these unique patients and reflect on experience from our center.
format Online
Article
Text
id pubmed-7224653
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher by the Society for Vascular Surgery. Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-72246532020-05-15 The need to manage the risk of thromboembolism in COVID-19 patients Khan, Inayat Hussain Savarimuthu, Sugeevan Leung, Marco Shiu Tsun Harky, Amer J Vasc Surg COVID-19 and vascular disease COVID-19 first appeared in Wuhan, Hubei Province, China, in December 2019. Thought to be of zoonotic origin, it has been named SARS-CoV-2 (COVID-19) and has spread rapidly. As of April 20, 2020, there have been >2.4 million cases recorded worldwide. The inflammatory process, cytokine storm, and lung injury that are associated with COVID-19 can put patients at an increased risk of thrombosis. The total incidence of thrombotic events in COVID-19 patients is currently uncertain. Those with more severe disease and with other risk factors, including increasing age, male sex, obesity, cancer, comorbidities, and intensive care unit admission, are at higher risk of these events. However, there is little international guidance on managing these risks in COVID-19 patients. In this paper, we explore the current evidence and theories surrounding thrombosis in these unique patients and reflect on experience from our center. by the Society for Vascular Surgery. Published by Elsevier Inc. 2020-09 2020-05-14 /pmc/articles/PMC7224653/ /pubmed/32417304 http://dx.doi.org/10.1016/j.jvs.2020.05.015 Text en © 2020 by the Society for Vascular Surgery. Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle COVID-19 and vascular disease
Khan, Inayat Hussain
Savarimuthu, Sugeevan
Leung, Marco Shiu Tsun
Harky, Amer
The need to manage the risk of thromboembolism in COVID-19 patients
title The need to manage the risk of thromboembolism in COVID-19 patients
title_full The need to manage the risk of thromboembolism in COVID-19 patients
title_fullStr The need to manage the risk of thromboembolism in COVID-19 patients
title_full_unstemmed The need to manage the risk of thromboembolism in COVID-19 patients
title_short The need to manage the risk of thromboembolism in COVID-19 patients
title_sort need to manage the risk of thromboembolism in covid-19 patients
topic COVID-19 and vascular disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7224653/
https://www.ncbi.nlm.nih.gov/pubmed/32417304
http://dx.doi.org/10.1016/j.jvs.2020.05.015
work_keys_str_mv AT khaninayathussain theneedtomanagetheriskofthromboembolismincovid19patients
AT savarimuthusugeevan theneedtomanagetheriskofthromboembolismincovid19patients
AT leungmarcoshiutsun theneedtomanagetheriskofthromboembolismincovid19patients
AT harkyamer theneedtomanagetheriskofthromboembolismincovid19patients
AT khaninayathussain needtomanagetheriskofthromboembolismincovid19patients
AT savarimuthusugeevan needtomanagetheriskofthromboembolismincovid19patients
AT leungmarcoshiutsun needtomanagetheriskofthromboembolismincovid19patients
AT harkyamer needtomanagetheriskofthromboembolismincovid19patients